Thursday, October 8, 2026
Via News Knowledge File

Apple Podcasts

organization80% conf.·synced Aug 13, 2026

Major podcast platform at forefront of personalized recommendation algorithms and content distribution

27
sourced metrics
435
relationships
10
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
252.89USD
Buyback Spending
816billion_USD
Shares Retired
44percent
Etf Weight
14.33percent
Forward Pe Ratio
33ratio
Portfolio Weight Vgt
15.8percent
Portfolio Weight
15.8percent
Unit Shipments
220000000iPhones
Market Share
90percent
Portfolio Weight In Qqq
7.33percent
Jul 2, 2026source
Investment Return On Double Down
51615USD
Apr 27, 2026source
Market Cap
4000USD
Apr 20, 2026source
Ownership Stake
20percent
Apr 2, 2026source
Index Weight
6.6percent
Mar 27, 2026source
Price To Earnings Ratio
32ratio
Mar 25, 2026source
Portfolio Percentage
20.1percent
Jan 1, 2026source
Share Buyback Total
816billion_USD
Dec 1, 2025source
Shares Repurchased
44percent
Dec 1, 2025source

Stated objectives

Ramp up development and release of three new AI wearable devices: glasses, pendant, and AirPods built around Siri

source
stated

Extend integrated hardware strategy into cloud by combining performance with sovereignty through proprietary AI infrastructure

source
by 2026-01-01 00:00:00stated

Become net zero carbon emissions

source
target: net zero by 2030-01-01 00:00:00stated

Sprint to build in-house chips and accelerate Apple silicon development

source
stated

Launch first foldable iPhone to build brand buzz around incoming CEO John Ternus and capture premium device segment

source
target: 2000 USD per unit stated

Launch revamped Siri powered by Gemini as its foundation model

source
by 2026-01-01 00:00:00stated

Obtain White House approval to purchase semiconductor chips from Chang Xin Memory Technologies despite its Pentagon blacklist status

source
stated

Favor better on-device processing of third-party AI software over building competing generative AI, lowering overspending risk

source
stated

Give customers a more flexible way to pay for Apple products through a leasing program available both online and in-store.

source
stated

Make a big smart home push with Siri AI at the center

source
stated

Relationship graph · 435 connections

Developed by
90
Competes with
64
Invested in
60
Supplies to
41
Employs
27
Owns
26
Customer of
23
Covered by
22
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com